Status of patients with acute myocardial infarction afterAsparcam-L, Panangin and potassium and magnesiumasparaginate therapy
- 作者: Petrov VI1, Bakumov PA1, Glinskaya AV1, Voronin SP1, Petrov VI1, Bakumov PA1, Glinskaya AV1, Voronin SP1
-
隶属关系:
- 期: 卷 3, 编号 4 (2006)
- 页面: 28-31
- 栏目: Articles
- URL: https://journals.eco-vector.com/1994-9480/article/view/117873
- ID: 117873
如何引用文章
全文:
详细
122 patients with acute myocardial infarction participated in the study. They received standard therapy and Asparcam-L or Panangin, or potassium and magnesium asparaginate. Efficiency and safety was studied with ECG, echocardiogram, quality of life questionnaires and laboratory methods. Asparcam-L presented good tolerance, safety and efficiency during acute myocardial infarction treatment, as well as a better prognosis.
参考
- Иежица И. И., Спасов А. А., Петров В. И. и др. // Микроэлементы в медицине: Матер. I съезда РОСМЭМ. 2004. Т. 5, вып. 4. С. 62-64.
- Elliott M., Antman M. D. // Circulation. 1995. Vol. 92. P. 2367-2372.
- Herzog W., Sereruary V. L. // Coronary Artery Disease. 1996. Vol. 7. P. 364-371.
- The MAGIC Steering Committee. Rationale and design of the Magnesium in Coronaries (MAGIC) Study: A clinical trial to reevaluate the efficacy of early adminstration of magnesium in acute myocardial infarction // Am. Heart J. 2000. № 139. P. 10-14.
- The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management // Eur. Heart J. 1996. № 17. P. 43-63.
- Woods K. L. // Lancet. 1995. Vol. 346. P. 611-14.
补充文件
